BridgeBio Pharma (BBIO) Tax Provisions (2024 - 2025)
BridgeBio Pharma (BBIO) reported Tax Provisions of -$165000.0 for Q4 2025, down 114.31% on a YoY basis from $1.2 million in Q4 2024, and up 89.32% sequentially from -$1.5 million in Q3 2025.
BridgeBio Pharma (BBIO) Tax Provisions (2024 - 2025) Analysis & Trends
BridgeBio Pharma (BBIO) has 2 years of Tax Provisions data on file, last reported at -$165000.0 in Q4 2025.
- For the quarter ending Q4 2025, Tax Provisions fell 114.31% year-over-year to -$165000.0; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (changed N/A YoY), and the FY2025 full-year result was $435000.0, down 62.27% from the prior year.
- Tax Provisions rose to -$165000.0 in Q4 2025, from -$1.5 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $2.1 million in Q2 2025 to a low of -$1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 31.86 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 179.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | BridgeBio Pharma | 16.15 Bn | 15.22 Bn | 184.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -165,000.00 |
| Sep 30, 2025 | -1.55 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Dec 31, 2024 | 1.15 Mn |